Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Champions Oncology (CSBR) stocks

Learn how to easily invest in Champions Oncology stocks.

Champions Oncology is a biotechnology business based in the US. Champions Oncology stocks (CSBR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.54 – an increase of 2.24% over the previous week. Champions Oncology employs 194 staff and has a trailing 12-month revenue of around $46.8 million.

How to buy stocks in Champions Oncology

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CSBR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Champions Oncology stock price (NASDAQ:CSBR)

Use our graph to track the performance of CSBR stocks over time.

Champions Oncology shares at a glance

Information last updated 2022-06-24.
Latest market close$7.76
52-week range$6.81 - $11.25
50-day moving average $7.54
200-day moving average $8.47
Wall St. target price$14.67
PE ratio 861.1112
Dividend yield $0 (0%)
Earnings per share (TTM) $0.01

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
3.8 / 5
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Champions Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Champions Oncology price performance over time

Historical closes compared with the close of $7.76 from 2022-06-27

1 week (2022-06-21) 2.24%
1 month (2022-05-24) 5.15%
3 months (2022-03-24) -2.76%
6 months (2021-12-24) N/A
1 year (2021-06-28) -26.72%
2 years (2020-06-26) -13.59%
3 years (2019-06-28) 7.83
5 years (2017-06-28) 173.24%

Is Champions Oncology under- or over-valued?

Valuing Champions Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Champions Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Champions Oncology's P/E ratio

Champions Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 861x. In other words, Champions Oncology shares trade at around 861x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Champions Oncology's EBITDA

Champions Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 million.

The EBITDA is a measure of a Champions Oncology's overall financial performance and is widely used to measure a its profitability.

Champions Oncology financials

Revenue TTM $46.8 million
Operating margin TTM 0.58%
Gross profit TTM $19.6 million
Return on assets TTM 0.57%
Return on equity TTM 2.56%
Profit margin 0.47%
Book value $0.68
Market capitalisation $104.8 million

TTM: trailing 12 months

Champions Oncology share dividends

We're not expecting Champions Oncology to pay a dividend over the next 12 months.

Have Champions Oncology's shares ever split?

Champions Oncology's shares were split on a 1:12 basis on 11 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.

Champions Oncology share price volatility

Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $6.81 up to $11.25. A popular way to gauge a stock's volatility is its "beta".

CSBR.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 1.0272. This would suggest that Champions Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Champions Oncology overview

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site